Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.46 |
| ▸ | UBE2M | P61081 | 1/20 | 0.45 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1821857 | 0.89 | DRD2 (0.52) | DRD2UBE2MDCUN1D1 | |
| SCHEMBL4823773 | 0.81 | DRD2 (1.00) | DRD2SLC6A4UBE2MDCUN1D1ALDH1A1 | |
| SCHEMBL2927216 | 0.80 | DRD2 (0.44) | DRD2P2RY14UBE2MDCUN1D1 | |
| SCHEMBL28689880 | 0.80 | DRD2 (0.66) | DRD2SLC6A4P2RY14ALDH1A1SMN1; SMN2 | |
| SCHEMBL28876087 | 0.78 | NOTUM (0.47) | DRD2 | |
| SCHEMBL8207578 | 0.77 | DRD2 (0.73) | DRD2SLC6A4 | |
| SCHEMBL2923960 | 0.77 | ALDH1A1 (0.52) | DRD2ALDH1A1SMN1; SMN2 | |
| SCHEMBL1009377 | 0.77 | DRD2 (0.68) | DRD2SLC6A4 | |
| Hydrochloric Acid SCHEMBL1010782 | 0.76 | DRD2 (0.67) | DRD2SLC6A4 | |
| SCHEMBL18640401 | 0.76 | CARM1 (0.56) | DRD2UBE2MDCUN1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501777-B2 | 1-ethyl-4-[3-fluoro-5-(methylsulfonyl)phenyl]piperidine; central nervous system disorders, Parkinson's disease, Parkinsonism, dyskinesias, including L-DOPA induced dyskinesias, dystonias, tics, tremor, Huntington disease | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2013-08-06 | — | — | US | disclosed |
| US-8501777-B2 | 1-ethyl-4-[3-fluoro-5-(methylsulfonyl)phenyl]piperidine; central nervous system disorders, Parkinson's disease, Parkinsonism, dyskinesias, including L-DOPA induced dyskinesias, dystonias, tics, tremor, Huntington disease | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2013-08-06 | — | — | US | disclosed |
| US-8501777-B2 | 1-ethyl-4-[3-fluoro-5-(methylsulfonyl)phenyl]piperidine; central nervous system disorders, Parkinson's disease, Parkinsonism, dyskinesias, including L-DOPA induced dyskinesias, dystonias, tics, tremor, Huntington disease | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2013-08-06 | — | — | US | disclosed |
| EP-2155669-B1 | NEW DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2011-05-04 | — | — | EP | disclosed |
| EP-1948606-B1 | 3, 5-DISUBSTITUTED PHENYL-PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2011-01-05 | — | — | EP | disclosed |
| EP-1948606-B1 | 3, 5-DISUBSTITUTED PHENYL-PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2011-01-05 | — | — | EP | disclosed |
| EP-1963268-B1 | DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2010-12-01 | — | — | EP | disclosed |
| EP-1963268-B1 | DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2010-12-01 | — | — | EP | disclosed |
| US-20100197760-A1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-08-05 | — | — | US | disclosed |
| US-RE41315-E1 | Modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20080234321-A1 | 3,5-Disubstituted Phenyl-Piperidines as Modulators of Dopamine Neurotransmission | SANIONA AB (DK) | 2008-09-25 | — | — | US | disclosed |
| US-20080234321-A1 | 3,5-Disubstituted Phenyl-Piperidines as Modulators of Dopamine Neurotransmission | SANIONA AB (DK) | 2008-09-25 | — | — | US | disclosed |
| EP-1963268-A1 | DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | Neurosearch Sweden AB (SE) | 2008-09-03 | — | — | EP | disclosed |
| EP-1419773-B1 | 4-Phenylpiperidine derivatives as modulators of dopamine neurotransmission | NEUROSEARCH SWEDEN AB (SE) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007065655-A1 | DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NEUROSEARCH SWEDEN AB (SE) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007065655-A1 | DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NEUROSEARCH SWEDEN AB (SE) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007042295-A1 | 3, 5-DISUBSTITUTED PHENYL-PIPERIDINES AS MDULATORS OF DOPAMINE? NEUROTRANSMISSION | NEUROSEARCH SWEDEN AB (SE) | 2007-04-19 | — | — | WO | disclosed |
| US-6924374-B2 | Central nervous system disorders; psychological disorders | A. CARLSSON RESEARCH AB (SE) | 2005-08-02 | — | — | US | disclosed |
| EP-1419773-A2 | 4-Phenylpiperidine derivatives as modulators of dopamine neurotransmission | A. Carlsson Research AB (SE) | 2004-05-19 | — | — | EP | disclosed |
| US-20030004169-A1 | Modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2003-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234321-A1 | 3,5-Disubstituted Phenyl-Piperidines as Modulators of Dopamine Neurotransmission | SLC6A3, DRD2, DRD3 | DRD2 2/4885SLC6A4 19/4885P2RY14 448/4885 |
| US-20100197760-A1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | SLC6A2, SLC6A3, SLC18A2 | DRD2 6/4885SLC6A4 12/4885P2RY14 318/4885 |
| US-20030004169-A1 | Modulators of dopamine neurotransmission | OPRD1, OPRK1, OPRM1 | DRD2 16/4885SLC6A4 231/4885P2RY14 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.